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Abstract
Achieving viral suppression among HIV-positive persons is a critical component of HIV treatment 
and prevention, because it leads to improved health outcomes for the individual and reduced risk 
of HIV transmission. There is wide variation in viral suppression across jurisdictions, races/
ethnicities, age groups, and transmission risk groups. This analysis uses HIV surveillance data to 
examine rates of viral suppression among people living with diagnosed HIV (PLWDH) in 38 
jurisdictions with complete lab reporting. Among people who received a diagnosis in 2014, the 
percentage with viral suppression within 12 months of diagnosis and the average time to viral 
suppression was assessed. Overall, among PLWDH in 2014, 57.9% were virally suppressed, and, 
among people with HIV diagnosed in 2014, 68.2% were suppressed within 12 months of diagnosis 
with an average time to suppression of 6.9 months. All outcomes varied by jurisdiction, but most 
had similar patterns of disparities with a few exceptions. These data highlight the need for tailored 
interventions at the local level. In addition, jurisdictions with relatively low viral suppression 
among particular groups could adapt effective interventions from jurisdictions who have higher 
rates of suppression.
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Introduction
A critical component of HIV treatment and prevention programs is viral suppression among 
HIV-positive persons. Viral suppression not only leads to improved health outcomes for the 
individual, but can also reduce the risk of HIV transmission [1, 2]. Given the importance of 
viral suppression, increasing the percentage of persons living with diagnosed HIV (PLWDH) 
who are virally suppressed to 80% has been set as a national goal in the United States [3]. 
Among PLWDH at year-end 2014 in the United States, only 57.9% were virally suppressed, 
and this varied by race/ethnicity, age, transmission category, and state [4]. For example, 
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among black/African American (hereafter referred to as black) PLWDH, 51.5% were virally 
suppressed compared to 65.0% of white PLWDH. Among the 38 jurisdictions included in 
the report, the percentage virally suppressed ranged from a low of 34.3% in Virginia to a 
high of 78.8% in Montana. These disparities suggest a need for local interventions tailored 
to the population segments most in need to eliminate the disparities and achieve the national 
goal. To aid in this process, this analysis uses national HIV surveillance data to examine 
disparities at the jurisdiction level to reveal variations in the profile of disparities that may be 
masked at the national level.
Methods
Data from the National HIV Surveillance System (NHSS) reported to CDC through 
December 2016 were used to determine the number of persons living with diagnosed HIV 
and the percentage of persons who were virally suppressed during 2014. We also determined 
the percentage of persons who received a diagnosis during 2014 who were virally 
suppressed within 12 months of diagnosis and the average time to viral suppression. As of 
December 2016, 38 jurisdictions had met the following criteria for the collection and 
reporting of CD4+ T-lymphocyte (CD4) and viral load (VL) test results: (1) the 
jurisdiction’s laws or regulations required the reporting of all CD4 and VL results to the 
state or local health department; (2) laboratories that perform HIV-related testing for the 
jurisdiction had reported at least 95% of HIV-related test results to the health department; (3) 
the jurisdiction had reported to CDC at least 95% of all CD4 and VL test results received 
since January 2014. The 38 jurisdictions were Alabama, Alaska, California, Colorado, 
Connecticut, Delaware, the District of Columbia, Georgia, Hawaii, Illinois, Indiana, Iowa, 
Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, 
Montana, Nebraska, New Hampshire, New Mexico, New York, North Dakota, Oregon, 
Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, 
West Virginia, Wisconsin, and Wyoming.
Viral suppression during 2014 was assessed among persons with HIV diagnosed by 
December 31, 2013 and who were alive as of December 31, 2014. Viral suppression was 
defined as having a VL result less than 200 copies per milliliter at the most recent VL test 
during 2014. The percentage of all persons living with diagnosed or undiagnosed HIV who 
are virally suppressed was also calculated using the estimated number of persons living HIV.
[4] Viral suppression within 12 months of diagnosis was assessed among persons with HIV 
diagnosed in 2014 and who were alive for at least 12 months after diagnosis. Time to viral 
suppression was calculated using Kaplan-Meier survival analysis method with 12 months of 
observation. All analyses were restricted to persons who were 13 years or older either at 
diagnosis (time to viral suppression and viral suppression within 12 months of diagnosis) or 
at year-end 2013 (viral suppression during 2014). Area of residence for the time to viral 
suppression and viral suppression within 12 months of diagnosis was based on residence at 
HIV diagnosis; for analysis on viral suppression during 2014 among persons living with 
HIV, residence was based on most recent known address at the end of 2014. All analyses 
were stratified by jurisdiction, and viral suppression during 2014 were further stratified by 
age group, race/ethnicity, and transmission category, so disparities could be evaluated. To 
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account for missing risk factor information, transmission category was adjusted using 
multiple imputation [5].
Results
Overall, among PLWDH in 2014 in the 38 jurisdictions, 57.9% were virally suppressed, and, 
among all persons living with diagnosed or undiagnosed HIV, viral suppression was 47.3% 
(Table 1). Viral suppression was higher among whites (65.0%) than blacks (51.5%) or 
Hispanics/Latinos (58.2%). This disparity persisted in most jurisdictions with a relative 
difference of 10% or higher in many areas (Figure 1). In three jurisdictions viral suppression 
was higher among blacks than whites by at least a relative difference of 5%; Wyoming 
(relative difference: 18%), North Dakota (relative difference: 11%), and Rhode Island 
(relative difference: 5%). The areas with the largest disparity between blacks and whites 
were West Virginia (relative difference: −37%) and South Dakota (relative difference: 
−31%). In one jurisdiction viral suppression was higher among Hispanics/Latinos than 
whites (Maryland, relative difference: 5%). The areas with the largest disparity between 
Hispanics/Latinos and whites were South Dakota (relative difference: −42%) and Louisiana 
(relative difference: −38%).
In general, viral suppression was higher among older age groups in all regions (Figure 2), 
although the age gradient was less pronounced in the Northeast compared to the other 
regions. The relative difference between the youngest and oldest age groups was 14% in the 
Northeast compared to approximately 20% in all other regions. The areas with the least 
variation in viral suppression by age group were Rhode Island, Virginia, and Wisconsin. 
Two areas had the opposite pattern with the youngest age group having higher viral 
suppression than the oldest age group; Colorado and North Dakota.
By transmission category, viral suppression was highest among males with infection 
attributed to male-to-male sexual contact (men who have sex with men, MSM; 61.2%) and 
lowest among males with infection attributed to injection drug use (IDU; 48.4%; Table 2). 
The area with the highest viral suppression among MSM was Montana (80.8%) and the 
lowest was Virginia (34.1%). The area with the highest viral suppression among persons 
with infection attributed to IDU was Alaska (males: 75.4%, females: 79.7%) and the lowest 
among male persons who inject drugs (PWID) was Utah (26.5%) and among female PWID 
was South Dakota (32.8%). The area with the highest viral suppression among persons with 
infection attributed to male-to-male sexual contact and IDU (MSM/IDU) was North Dakota 
(86.0%) and the lowest was South Dakota (11.4%). The area with the highest viral 
suppression among persons with infection attributed to heterosexual contact was Montana 
(males: 85.2%, females: 79.8%) and the lowest was Virginia (males: 34.3%, females: 
34.8%). In most areas, MSM had higher viral suppression than all other transmission 
categories with a couple notable exceptions (Figure 3). In Alaska, male and female PWID, 
MSM/IDU, and females with infection attributed to heterosexual contact all had higher viral 
suppression than MSM. In North Dakota, female PWID, MSM/IDU, and females with 
infection attributed to heterosexual contact all had higher viral suppression than MSM. In 
addition, females with infection attributed to heterosexual contact in Colorado (relative 
difference: 18%), female PWID in Rhode Island (relative difference: 14%), male PWID in 
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Nebraska (relative difference: 11%), and MSM/IDU in Virginia (relative difference: 17%) all 
had higher viral suppression than MSM in the respective jurisdictions.
Among persons who received an HIV diagnosis in 2014, 68.2% were virally suppressed 
within 12 months of diagnosis (Table 3). This varied by jurisdiction from a high of 92.3% in 
Montana to a low of 59.7% in the District of Columbia. Time to viral suppression was 6.9 
months overall with a range of 4.5 months in Montana to 7.8 months in Mississippi and the 
District of Columbia. Six jurisdictions attained at least 80% viral suppression within 12 
months of diagnosis with an average time to viral suppression under 6 months; Connecticut, 
Iowa, Maine, Montana, New Hampshire, and Washington.
Discussion
Overall, in our analysis of viral suppression among PLWDH at year-end 2014 in 38 
jurisdictions, none reached the national goal of 80%, but Montana was within 2 percentage 
points and six others had at least 70% viral suppression. This was an improvement over the 
2013 viral suppression rates – only two jurisdictions out of 33 had at least 70% suppression 
[6]. When examining sub-populations, we found similar patterns of disparity across 
jurisdictions. In almost all jurisdictions whites had a higher rate of viral suppression then 
blacks or Hispanics/Latinos. There were only a few exceptions to this pattern and these were 
mostly in low-morbidity states where small year-to-year changes in numbers may result in 
large percent changes. The observation that viral suppression increases with age also held 
true in most jurisdictions. There were only two jurisdictions where viral suppression was 
higher among younger age groups than older. Further study of the jurisdictions that have 
high viral suppression among younger age groups may reveal particularly effective strategies 
that could be shared with other jurisdictions. In general, MSM had higher rates of viral 
suppression than PWID and those with infections attributed to heterosexual contact. One 
state with high viral suppression among PWID was Alaska. Determining factors that 
contributed to this outcome could help other jurisdictions attain similar results.
In addition to having a high level of viral suppression among all PLWDH, it is also 
important for people with newly diagnosed HIV to be promptly linked to care to attain viral 
suppression quickly to reduce their window of infectiousness as well as to improve their 
health outcomes. Among people who received a diagnosis in 2014, 68% were virally 
suppressed within 12 months. Six jurisdictions had at least 80% viral suppression among 
persons who received a diagnosis in 2014. These jurisdictions met the national goal for viral 
suppression among these persons [3] and may serve as models for best practices for attaining 
a high rate of viral suppression. Four of these jurisdictions also met the national goal of 
linking 85% of people receiving an HIV diagnosis in 2014 to care within one month of 
diagnosis [6]. Effective interventions that can help improve viral suppression rates include 
interventions to support linkage and retention in care, such as linkage coordination and case 
management [7], and treatment adherence through support with mobile applications [8]. 
Public health departments and care providers can identify people who may be out of care 
and need re-engagement services or who are not virally suppressed and need treatment 
adherence counseling through surveillance or medical record data [9]. Ensuring all 
population segments have access to treatment as recommended will require addressing the 
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challenges persons with HIV face with inadequate health insurance, comorbidities, mental 
health or substance misuse issues, or other social or economic disadvantages such as stigma 
or lack of transportation [10, 11].
This analysis is subject to at least the following limitations. First, we could only include 38 
jurisdictions in the analysis, because complete lab reporting is necessary to accurately 
measure viral suppression rates. Therefore, the overall results may not be representative of 
all PLWDH in the United States and we could not evaluate disparities in viral suppression 
within all 50 states. However, the jurisdictions included in our analyses represent 72% of 
PLWDH and 71% of persons with HIV diagnosed in 2014 in the United States. Second, area 
of residence for viral suppression during 2014 among all PLWDH was based on most recent 
known address as of the end of 2014. If the most recent address in the surveillance data did 
not accurately reflect where an individual was living at the time, then they may be classified 
into the wrong jurisdiction.
These data highlight the need for tailored interventions at the local level. There are wide 
variations in the rate of viral suppression across jurisdictions as well as variations in 
disparity profiles, which suggests a one-size-fits-all approach will not be effective. However, 
there are opportunities for jurisdictions to learn from each other. Those jurisdictions who 
have relatively low viral suppression among particular groups could adapt effective 
interventions from similar jurisdictions with higher rates of viral suppression. Health care 
providers, state and local health departments, and community-based organizations can 
collaborate to develop effective interventions and the services and infrastructure needed to 
promote engagement in care and adherence to medication, which can lead to the desired 
outcome of viral suppression [12].
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Figure 1. 
Disparity in viral suppression among persons living with diagnosed HIV, by jurisdiction and 
race/ethnicity, 2014
Note. The comparison group was white.
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Figure 2. 
Viral suppression among persons living with diagnosed HIV, by jurisdiction, region, and 
age, 2014
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Figure 3. 
Disparity in viral suppression among persons living with diagnosed HIV, by jurisdiction and 
transmission category, 2014
Note. IDU, injection drug use; The comparison group was persons with infection attributed 
to male-to-male sexual contact.
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Table 3
Percentage with viral suppression at 12 months after diagnosis, and time to viral suppression, among persons 
with HIV diagnosed in 2014, 38 U.S. Jurisdictions
Diagnosis Viral suppression within 12mo of diagnosis Time to viral suppression
Jurisdiction N Col % % Months (SE)
Alabama 670 2.4 70.5 6.9 (0.16)
Alaska 39 0.1 69.2 5.4 (0.43)
California 5,061 17.8 67.6 6.9 (0.06)
Colorado 377 1.3 77.8 6.5 (0.20)
Connecticut 290 1.0 81.6 5.4 (0.24)
Delaware 115 0.4 68.8 6.4 (0.41)
District of Columbia 411 1.5 59.7 7.8 (0.21)
Georgia 2,340 8.2 63.2 7.3 (0.09)
Hawaii 99 0.4 75.8 6.0 (0.42)
Illinois 1,527 5.4 61.6 7.3 (0.11)
Indiana 461 1.6 64.2 7.5 (0.19)
Iowa 94 0.3 86.5 5.0 (0.34)
Louisiana 1,214 4.3 65.5 7.4 (0.12)
Maine 55 0.2 87.3 4.7 (0.54)
Maryland 1,272 4.5 61.3 7.4 (0.13)
Massachusetts 659 2.3 79.9 5.0 (0.17)
Michigan 780 2.7 68.6 7.1 (0.15)
Minnesota 303 1.1 72.5 6.0 (0.25)
Mississippi 481 1.7 61.4 7.8 (0.19)
Missouri 467 1.6 74.1 6.5 (0.19)
Montana 14 0.1 92.3 4.5 (0.67)
Nebraska 88 0.3 72.6 6.0 (0.41)
New Hampshire 41 0.1 85.4 5.4 (0.58)
New Mexico 135 0.5 74.8 6.3 (0.36)
New York 3,368 11.9 74.8 6.1 (0.07)
North Dakota 20 0.1 65.0 7.2 (1.08)
Oregon 242 0.9 71.2 6.8 (0.26)
Rhode Island 96 0.3 79.0 5.6 (0.43)
South Carolina 757 2.7 73.1 7.0 (0.15)
South Dakota 28 0.1 64.3 6.1 (0.76)
Tennessee 747 2.6 63.6 7.6 (0.15)
Texas 4,399 15.5 66.2 7.2 (0.06)
Utah 113 0.4 76.8 6.4 (0.39)
Virginia 912 3.2 61.6 7.5 (0.14)
Washington 437 1.5 80.4 5.2 (0.20)
West Virginia 89 0.3 77.1 6.5 (0.45)
Wisconsin 219 0.8 78.6 5.7 (0.28)
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Diagnosis Viral suppression within 12mo of diagnosis Time to viral suppression
Jurisdiction N Col % % Months (SE)
Wyoming 10 0.0 70.0 7.4 (1.26)
Total 28,430 100 68.2 6.9 (0.03)
Note. Diagnosis exclude those where month of diagnosis or death is missing, or if death occurred before diagnosis.
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